Sight Sciences/SGHT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Sight Sciences

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma and the SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids in adult patients with evaporative dry eye disease due to meibomian gland disfunction.

Ticker

SGHT

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Paul Badawi

Employees

214

Headquarters

Menlo park, United States

Sight Sciences Metrics

BasicAdvanced
$326M
Market cap
-
P/E ratio
-$1.12
EPS
-
Beta
-
Dividend rate
$326M
$9.67
$1.04
159K
13.007
12.419
30.856
30.856
-14.76%
-31.09%
-42.84%
-33.65%
4.005
2.977
2.989
8.27%
32.87%
43.14%

What the Analysts think about Sight Sciences

Analyst Ratings

Majority rating from 6 analysts.
Hold

Sight Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-84.37% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$19M
2.67%
Net income
-$16M
52.83%
Profit margin
-84.37%
48.85%

Sight Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 19.71%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.30
-$0.27
-$0.22
-$0.33
-
Expected
-$0.34
-$0.32
-$0.32
-$0.28
-$0.30
Surprise
-12.13%
-15.05%
-30.60%
19.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Sight Sciences stock?

Sight Sciences (SGHT) has a market cap of $326M as of June 17, 2024.

What is the P/E ratio for Sight Sciences stock?

The price to earnings (P/E) ratio for Sight Sciences (SGHT) stock is 0 as of June 17, 2024.

Does Sight Sciences stock pay dividends?

No, Sight Sciences (SGHT) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Sight Sciences dividend payment date?

Sight Sciences (SGHT) stock does not pay dividends to its shareholders.

What is the beta indicator for Sight Sciences?

Sight Sciences (SGHT) does not currently have a Beta indicator.

What is the Sight Sciences stock price target?

The target price for Sight Sciences (SGHT) stock is $6.1, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sight Sciences stock

Buy or sell Sight Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing